Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04577404 · ClinicalTrials.gov registry record · Phase 3
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
A Phase 3 study, sponsored by Tanabe Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 124
- Enrollment target
NCT04577404 is a Phase 3 study that has completed, run by Tanabe Pharma America. The registered enrollment target is 124 participants.
The verdict
NCT04577404, a Phase 3 study, has completed, sponsored by Tanabe Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 124 participants
- Enrollment target
Study Summary
This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) for up to 96 weeks.
Interventions
- DRUG MT-1186
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2023-08-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04577404
The ClinicalTrials.gov registry entry for NCT04577404 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma America, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MT-1186 is the first listed.
NCT04577404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04577404 about?
NCT04577404 is a clinical study titled "Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)". This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) for up to 96 weeks.
What is the current status of trial NCT04577404?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2020-10-29. Estimated completion is 2023-08-09.
What interventions are being tested in trial NCT04577404?
The interventions under investigation include: MT-1186 (DRUG).
Who is sponsoring clinical trial NCT04577404?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.